Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck meets Street estimate

MRK reported second quarter EPS of $0.79, in line with Street's estimate

Read the full 121 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE